Emerphed Generic: When Will Generic Ephedrine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Emerphed Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2027 to 2028 A wide window Why then?
- Has the FDA approved a generic? August 2017 12 companies approved
- When does the last patent end? May 2040 5 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Yes 20 companies list one
It already is. A generic ephedrine sulfate is listed for sale by 20 companies, so ask your pharmacy whether it can fill your prescription with one.
Why 2027 to 2028?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. We rate it probable: more likely than not, but it can still move.
If Emerphed’s last patent runs to May 2040, how can a generic come sooner?
The 5 patents that run past the expected month, to May 2040 (11,090,278, 11,241,400, 11,464,752, 11,478,436 and 1 more), cover a way of using it and the product’s formulation. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, a settlement between the companies sets the date. Generic companies have been challenging Emerphed’s patents with the FDA since October 2021. That is why the expected month comes before the last protection ends. See the road to a generic
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Emerphed, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Emerphed by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Strong 4 companies have filed, 1 first in line
- Brand sales
- $29M a yearSmaller seller
- FDA approved 2020 April 2020 FDA Orange Book
- Patents listed 5 last runs to May 2040 FDA Orange Book
- Generics FDA-approved 12 companies, the first approved August 2017 FDA Orange Book
- Medicaid prescriptions 864 in the last four reported quarters, $44.7K CMS Medicaid drug utilization, to Q1 2026
Emerphed’s Road to a Generic
Emerphed has had the market to itself since the FDA approved it in April 2020 (Nexus Pharmaceuticals LLC). Its 5 listed patents run to May 2040. Generic companies have challenged its patents with the FDA since October 2021.
The first generic of Emerphed is expected between 2027 and 2028.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
Why a Generic Can Come Before May 2040
The last listed patent runs to May 2040, but it covers a way of using it and the product’s formulation, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Emerphed Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Emerphed’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 11,090,278 | A way of using it (U-3183) | May 2040 | Active |
| 11,241,400 | A way of using it (U-3183) | May 2040 | Active |
| 11,464,752 | The product’s formulation | May 2040 | Active |
| 11,478,436 | A way of using it (U-3183) | May 2040 | Active |
| 11,571,398 | A way of using it (U-3183) | May 2040 | Active |
Source: FDA Orange Book, application 213407. Patent numbers open the patent on Google Patents.
Patent Challenges to Emerphed
The first patent challenge to Emerphed reached the FDA in October 2021, from one company on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Emerphed’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Injection, 50 mg/10 mL | October 2021 | 1 company | Head start no longer applies decided October 2024 | Not yet | Not yet | May 2040 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Ephedrine Sulfate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
At least 12 companies have applied to the FDA to make generic ephedrine sulfate.
First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Emerphed’s patents with the FDA since October 2021: see the patent challenges.
Approved by the FDA
The FDA has approved generic versions from 12 companies, the first in August 2017. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic ephedrine sulfate is listed for sale by 20 companies. Ask your pharmacy whether it can fill your prescription with it.
Amneal Pharmaceuticals LLC, AuroMedics Pharma LLC, Baxter Healthcare Corporation, Caplin Steriles Limited, Civica, Inc., Dr. Reddy's Laboratories, Inc. and 14 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Sandoz Inc | August 2017 | 50MG/ML (50MG/ML) | AP |
| Amneal Eu Ltd | October 2019 | 50MG/ML (50MG/ML) | AP |
| Fresenius Kabi USA LLC | August 2020 | 25MG/5ML (5MG/ML), 50MG/10ML (5MG/ML), 50MG/ML (50MG/ML) | AP2, AP |
| Dr Reddys Laboratories Ltd | October 2020 | 50MG/ML (50MG/ML) | AP |
| Hikma Pharmaceuticals USA Inc | December 2020 | 25MG/5ML (5MG/ML), 50MG/ML (50MG/ML) | AP3, AP |
| Eugia Pharma Specialities Ltd | June 2021 | 50MG/ML (50MG/ML) | AP |
| Gland Pharma Ltd | February 2022 | 50MG/10ML (5MG/ML), 50MG/ML (50MG/ML) | AP, AP1 |
| Mankind Pharma Ltd | April 2022 | 50MG/ML (50MG/ML) | AP |
| Xiromed Pharma Espana Sl | April 2022 | 50MG/ML (50MG/ML) | AP |
| Sagent Pharmaceuticals Inc | March 2023 | 50MG/ML (50MG/ML) | AP |
| Caplin Steriles Ltd | July 2024 | 50MG/ML (50MG/ML) | AP |
| Baxter Healthcare Corp | July 2026 | 50MG/ML (50MG/ML) | AP |
| Zydus Pharmaceuticals USA Inc discontinued | May 2023 | 50MG/ML (50MG/ML) | – |
| Civica Inc discontinued | December 2025 | 50MG/ML (50MG/ML) | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Emerphed Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Emerphed, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Emerphed
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicaid Prescriptions by Quarter
864 prescriptions in the four quarters to Q1 2026, $44.7K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 148 | $2,624 |
| Q4 2025 | 250 | $25,147 |
| Q3 2025 | 243 | $4,325 |
| Q2 2025 | 223 | $12,644 |
| Q1 2025 | 508 | $76,480 |
Source: CMS Medicaid State Drug Utilization Data, over Emerphed’s own package codes.
Emerphed Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 50MG/10ML (5MG/ML) | Solution | Intravenous | April 2020 | Prescription reference product |
| 25MG/5ML (5MG/ML) | Solution | Intravenous | February 2023 | Prescription reference product |
Source: FDA Orange Book, Nexus Pharmaceuticals LLC. Listed for sale today by Nexus Pharamaceuticals Inc. (FDA NDC Directory).
Emerphed NDC Codes and Packages
Each Emerphed package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 14789-0250-10 | EPHEDRINE SULFATE 5 mg/mL injection | carton of 10 vials of 10 mL | Nexus Pharamaceuticals Inc. |
| 14789-0250-10 | EPHEDRINE SULFATE 5 mg/mL injection | carton of 10 vials of 10 mL | Nexus Pharamaceuticals Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Emerphed’s own FDA approval (NDA 213407) are listed, never a generic. Some codes belong to companies that repackage Emerphed: it is the same medicine in a different package.
What a Generic Emerphed Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Emerphed
Is there a generic for Emerphed right now?
Yes. The FDA NDC Directory lists a generic ephedrine sulfate from 20 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Emerphed go generic?
It already has. The FDA NDC Directory lists a generic ephedrine sulfate from 20 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic ephedrine sulfate be the same as Emerphed?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. At least 12 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Emerphed?
Yes. The FDA Orange Book lists approved generic versions from 12 companies, the first approved in August 2017: Sandoz Inc, Amneal Eu Ltd, Fresenius Kabi USA LLC, Dr Reddys Laboratories Ltd and 8 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Emerphed patent expire?
The FDA Orange Book lists 5 patents for Emerphed; the last runs to May 2040. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2027 to 2028) weighs all of that.
Has anyone challenged the Emerphed patents?
Yes. The first patent challenge to Emerphed reached the FDA in October 2021, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected 2027 to 2028 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- ZonisadeZonisamideSeptember 2027
- TwirlaEthinyl Estradiol and LevonorgestrelAugust 2028
- MitosolMitomycinMay 2029
- RapiblykLandiololApril 2034
- GvokeGlucagonApril 2036
- ClindesseClindamycin PhosphateTBD no date yet
About Emerphed
- Generic name ephedrine sulfate
- How it is taken Into a vein (IV)
- Company Nexus Pharmaceuticals LLC
- Patent challenges Since October 2021 (FDA)
- More drugs Brand-name drugs starting with E
- Have a question? A pharmacist answers, free. Ask about Emerphed
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.